Like planned, addition to recently opened Medtronic position with a purchase of 20 shares bought for 79,37 USD per share. Thesis is still in place: reasonable enough valuation, suitable sector and decent yield and dividend growth. Share price has trended down for quite some time and rightfully so, but in my opinion turning the trend slowly is likely enough. There are of course risks but in risk-reward terms I consider this package good enough. Main point is increasing the exposure to the medical sector which I will likely continue in coming months. Size of Medtronic position is still open but let’s see how valuations move. I would be inclined to add on Johnson & Johnson and Pfizer as well but intention is to only reinvest dollar dividends. Therefore ammunition is somewhat limited.